Abstract | OBJECTIVE: METHODS: For this systematic review and meta-analysis, we searched MEDLINE, EMBASE, SCOPUS, Cochrane Central Register of Controlled Trials, and Web of Science until 24th June 2021. We included randomized control trials that compared triple with dual therapy given to patients with lymphatic filariasis or endemic communities. This study was registered with PROSPERO (CRD42021266724). RESULTS: We included eight articles after the screening process. Triple therapy caused more clearance of microfilaria in the blood (RR: 1.52; 95% CI: 1.15, 2.02; p = 0.003), while dual therapy caused more clearance of the circulating filariae antigen in the blood (RR: 0.76; 95% CI: 0.65, 0.88; p = 0.0003), both 12 months after drug administration. The triple therapy had a similar adverse effect compared with the dual therapy group. CONCLUSION: Based on the greater efficacy in the clearance of microfilaria and the safety of triple therapy, it constitutes a better strategy for the eradication programs of lymphatic filariasis in endemic regions. However, further studies are needed to confirm our results.
|
Authors | Mohamed T Abuelazm, Basel Abdelazeem, Helmy Badr, Mohamed Gamal, Mohamed Ashraf, Sherief Abd-Elsalam |
Journal | Tropical medicine & international health : TM & IH
(Trop Med Int Health)
Vol. 27
Issue 3
Pg. 226-235
(03 2022)
ISSN: 1365-3156 [Electronic] England |
PMID | 35080325
(Publication Type: Journal Article, Meta-Analysis, Review, Systematic Review)
|
Copyright | © 2022 John Wiley & Sons Ltd. |
Chemical References |
- Filaricides
- Ivermectin
- Albendazole
- Diethylcarbamazine
|
Topics |
- Albendazole
(adverse effects)
- Animals
- Diethylcarbamazine
(adverse effects)
- Drug Therapy, Combination
- Elephantiasis, Filarial
(drug therapy)
- Filaricides
(adverse effects)
- Humans
- Ivermectin
(therapeutic use)
- Microfilariae
|